Discussing the Scientific Achievements and Social Impact of "GLP-1 Obesity Treatments"

National Academy of Science and Technology to Host Hallim International Symposium on October 16

An international symposium will be held to examine from multiple perspectives the research achievements and social impact of GLP-1 (Glucagon-Like Peptide-1) class obesity treatments, which have been attracting global attention.

The National Academy of Science and Technology announced that on October 16, it will host the 57th Hallim International Symposium both online and offline, under the theme of "GLP-1 Obesity Treatments."

Invitation to the 57th Hallim International Symposium Online. Provided by the National Academy of Science and Technology

GLP-1 is a hormone secreted from the intestines after meals, involved in blood sugar regulation and appetite suppression. Since its discovery in the 1980s, it has marked a major turning point in metabolic disease research and has recently emerged as a key substance in the development of obesity and diabetes treatments.

Experts from four countries will participate in this symposium to discuss the scientific discovery and therapeutic applications of GLP-1, as well as its social and economic impact. In addition, Korean experts from academia, industry, government, and the media will join to discuss the changes brought about by GLP-1 class drugs and policy responses.

President Chung Jin-ho stated, "GLP-1 treatments are a representative example of how fundamental scientific discoveries can lead to improvements in human health and social value." He added, "I hope this symposium will help the public understand the significance of scientific achievements and provide an opportunity for researchers in the field to engage in broad exchange."

This content was produced with the assistance of AI translation services.